Spectral Med Inc's stock took a hit, closing down 2.63% in yesterday's trading session.
In a challenging trading day, Spectral Med Inc (EDT.TO) saw its stock price decline by 2.63%, closing at CA$1.11. This drop reflects ongoing investor caution amidst the company's recent developments and the broader market environment.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$325.84M
52W high
$1.65
52W low
$1.03
1W change
-5.53%
Beta
0.22
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 183.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+183.8% Upside
Current Price
C$1.11
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
50.5%
Annualized
90-Day Vol
37.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.05 | C$0.88 – C$1.25 |
| 60 trading days | C$0.99 | C$0.77 – C$1.26 |
| 90 trading days | C$0.93 | C$0.69 – C$1.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain vigilant as Spectral Med Inc navigates its regulatory processes and market conditions. The recent decline may signal underlying concerns that need to be addressed.
Spectral Med Inc's stock down 2.63%
The market cap now stands at CA$325.84 million, reflecting investor sentiment and the challenges faced by the company.
Bull case
Supporters of Spectral Med Inc might highlight the recent FDA updates and progress in its PMA application for Toraymyxin™ as potential growth drivers. These developments could pave the way for future success and reassure investors about the company's direction.
Bear case
On the flip side, the stock's decline could suggest that investors are skeptical about the company's ability to meet its regulatory goals. There’s also a general wariness in the market regarding small-cap biotech stocks, which might be affecting investor confidence.
Market Reaction
Advertisement
The 2.63% decline in Spectral Med Inc's stock price yesterday may reflect a broader market sentiment where investors are cautious about small-cap biotech stocks. With no recent news to drive positive sentiment, the stock's performance may be influenced by external factors and market volatility.
Regulatory Landscape
Despite the recent drop, Spectral Med Inc has made progress with its PMA application for Toraymyxin™. The FDA's recent update indicated no additional clinical trials would be required, which could bode well for the company's future. However, investor confidence remains fragile as they await further developments.
Looking Ahead
As Spectral Med Inc continues to advance its regulatory submissions, investors will be closely monitoring the company's ability to meet its milestones. The recent stock decline serves as a reminder of the inherent risks in biotech investments, particularly for companies navigating complex approval processes.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
